UPB (Upstream Bio) Additional Paid-In Capital : $663.24 Mil(As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Additional Paid-In Capital?

Upstream Bio's quarterly additional paid-in capital increased from Sep. 2024 ($8.87 Mil) to Dec. 2024 ($660.60 Mil) and increased from Dec. 2024 ($660.60 Mil) to Mar. 2025 ($663.24 Mil).

Upstream Bio's annual additional paid-in capital increased from Dec. 2022 ($1.28 Mil) to Dec. 2023 ($4.82 Mil) and increased from Dec. 2023 ($4.82 Mil) to Dec. 2024 ($660.60 Mil).

Upstream Bio Additional Paid-In Capital Historical Data

The historical data trend for Upstream Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Additional Paid-In Capital Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

Additional Paid-In Capital

1.28

4.82

660.60

Upstream Bio Quarterly Data
	Dec22	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial			-	6.99	8.87	660.60	663.24

Upstream Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Upstream Bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.